Analysts at MLV & Co. initiated coverage on
SciClone Pharmaceuticals, Inc.SCLN with a Buy rating.
The target price for SciClone Pharmaceuticals is set to $15.
SciClone Pharmaceuticals shares have gained 78.29 percent over the past 52 weeks, while the S&P 500 index has surged 7.17 percent in the same period.
SciClone Pharmaceuticals' shares fell 0.21 percent to close at $9.36 on Friday.
Loading...
Loading...
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: